Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • 2021 Webinar: FY21 Peer Reviewed Cancer Research Program Funding Opportunities in Liver Cancer

    Product not yet rated Contains 2 Component(s) Recorded On: 04/12/2021

    Webinar hosted by the Public Policy Committee on April 12, 2021.

    The Peer Reviewed Cancer Research Program webinar will present funding opportunities for liver cancer through the Department of Defense. This webinar will cover topics including how to apply, what opportunities are available, as well as hints and tips on how to succeed in applying to the Department of Defense Congressionally Directed Medical Research Programs.

    Donna M. Kimbark

    Donna M. Kimbark, PhD currently serves as the Program Manager at the Congressionally Directed Medical Research Programs, U.S. Army Medical Research and Development Command.

    In 1996, Dr. Kimbark received her PhD in Molecular Pharmacology and Cancer Therapeutics from the State University of New York at Buffalo, Roswell Park Cancer Institute. Following postdoctoral training at Johns Hopkins Medical Institute, Dr. Kimbark worked in the biotechnology sector before joining the Congressionally Directed Medical Research Programs (CDMRP) in 2002 as Science Officer for the Breast Cancer Research Program. During her time as a Science Officer, Dr. Kimbark also served on the Institution Based Research Program group and served as Chair of the Consumer Working Group. While working in grants management, she received her certificate in Epidemiology and Biostatistics from Drexel University. In 2008, Dr. Kimbark was promoted to Program Manager for the Peer Reviewed Cancer Research Program.  Throughout her years at CDMRP, Dr. Kimbark has led multiple research funding programs including Autism, Multiple Sclerosis, Kidney Cancer, and Bone Marrow Failure Research Programs. Currently, she leads the program teams for the Peer Reviewed Cancer Research Program and the Melanoma Research Program.  In addition to her programmatic duties, Dr. Kimbark also leads the Funding Opportunities Announcement team, where she coordinates the creation and revisions solicitation templates for grants. For her efforts, she has been awarded the Commander’s Award for Civilian Service. Her areas of expertise include cancer therapeutics, pharmacology, proteomics, and scientific research administration.

  • 2021 Webinar: Simultaneous Liver Kidney Transplant: How Did We Do With the New Criteria?

    Product not yet rated Contains 2 Component(s) Recorded On: 03/29/2021

    Webinar hosted by the Liver Transplantation and Surgery Special Interest Group on March 29, 2021.

    In this one hour on-demand webinar, we will discuss how we arrived at the new organ allocation schema for simultaneous liver kidney (SLK) transplants by UNOS in partnership with our Transplant Nephrologists and the effect this has had on dual organ allocation and outcomes of SLK transplantation.

    Ryutaro Hirose

    Ryutaro Hirose, MD is professor and vice chair of clinical operations and value for the Department of Surgery at the University of California, San Francisco. He is an active liver, kidney and pancreas transplant surgeon. He currently serves as the Surgical Director of the Scientific Registry of Transplant Recipients (SRTR). He is a Councilor-at-large for the American Society of Transplant Surgeons (ASTS).

    Dr. Hirose has served as the chair of the ASTS Fellowship Training Committee and the ASTS Standards and Quality Committee. He spearheaded the creation and development of a National Transplant Quality Program with the ASTS and the American College of Surgeons. He has served as vice chair and chair of the UNOS Liver and Intestinal Organ Transplantation committee and led the development and implementation of the new liver distribution system, the national liver review board, HCC and MELD exception policy and the Simultaneous Liver Kidney Transplant (SLK). He has served on the board of directors and chair of the medical advisory board of donor network west, the local organ procurement agency for Northern California. Dr. Hirose has served as an associate editor for Clinical Transplantation. He has also served as the associate program director of the UCSF Surgical Residency program for over 15 years. His academic and scholarly interests include ischemia-reperfusion injury, hepatocellular carcinoma, transplant outcomes and organ allocation and distribution policy, with over 120 peer-reviewed articles in these specific areas. As an active educator and advisor, he has mentored over 100 surgical residents, medical students, fellows and junior faculty, both at UCSF and other institutions.

    Richard Formica

    Richard N. Formica Jr., MD is a professor of medicine and surgery, director of transplant medicine and the medical director of the Kidney Transplant Program at Yale University School of Medicine. Dr. Formica is a practicing transplant nephrologist. He is currently the President of the American Society of Transplantation and the OPTN/UNOS Regional 1 Associate Counselor and the Region 1 Representative to the OPTN/UNOS Membership and Professional Standards Committee.

    Dr. Formica has extensive expertise in public policy as it pertains to the solid organ transplantation. He been an active participant in the United Network of Organ Sharing since 2009. During this involvement he held leadership positions as the Chairman of the Kidney Paired Donation Work Group, the Kidney Transplantation Committee and the Simultaneous Liver-Kidney Transplantation Working Group. In these roles, he participated in the design, public vetting and implementation of public policy regarding, living kidney donation, deceased donor kidney allocation and the medically appropriated and fair allocation of deceased donor kidneys with deceased donor livers. Dr. Formica has been involved with the Clinical Trials in Organ Transplantation since inception, having been a site PI on CTOT-1, CTOT-9, CTOT -17 and currently is the site PI for CTOT -19. Dr. Formica has authored or co-authored 79 peer reviewed manuscripts and numerous book chapters. He is currently the Associate Editor for the Clinical Journal of the American Society of Nephrology responsible for the transplant portfolio.

    David Mulligan (Moderator)

    David C. Mulligan, MD, FACS, FAST, FAASLD is an abdominal organ transplant surgeon performing both living and deceased donor liver, kidney and pancreas transplants. He currently serves as Professor and Chair of Transplantation and Immunology in the Department of Surgery at Yale University School of Medicine/Yale New Haven Health System. His clinical and academic focus surrounds living donor liver transplantation, expanding donation, and working on ways to utilize ex-vivo organ perfusion systems to increase transplantation in the U.S.

    Dr. Mulligan’s leadership in solid organ transplantation across national and international platforms has grown considerably and he now serves as the President of the United Network of Organ Sharing (UNOS)/Organ Procurement Transplant Network (OPTN), Member At-Large on the Governing Board of the American Association for the Study of Liver Diseases, Chair of the Advisory Council on Transplantation (ACOT) to the Secretary of HHS, Special Government Employee for FDA Medical Device Advisory Committee and Chair of the Business Practice Committee of the American Society of Transplant Surgeons. In these visionary roles, he has led major changes in organ allocation and distribution and will hopefully culminate in substantial increases in organ transplants. Passionate about patient-centered care and building more resilient teams, he makes time to share his enjoyment of spending time in nature, especially near the ocean, with his wife and three children.

    Michael L. Schilsky (Moderator)

    Michael L. Schilsky, MD, FAASLD completed his medical education at the University of Chicago, Pritzker School of Medicine and then trained in internal medicine and gastroenterology at The Albert Einstein College of Medicine. After a post-doctoral training fellowship at the Liver Research Center of the Albert Einstein College of Medicine he joined the faculty there and rose to the rank of Associate Professor.

    Dr. Schilsky moved to The Mount Sinai School of Medicine in 1989 to begin his work in the field of liver transplantation and was recruited in 2003 to the Weill Cornell Medical Center where he partnered with the transplant program at Columbia Presbyterian. Dr. Schilsky was again recruited in 2007 to Yale as Medical Director for the Liver Transplant program and rose to the rank of Professor of Medicine and Surgery. He also is a member of the NIH sponsored Acute Liver Failure Study Group and chairs their publications committee. He is a former UNOS Region 1 representative for the Liver and Intestine Committee and is the current Chair of the Special Interest Group for Liver Transplantation and Surgery sponsored by the American Association for the Study of Liver Disease (AASLD).

  • Fundamentals of Liver Disease - Hepatitis C 2.0

    Contains 28 Component(s), Includes Credits Recorded On: 02/26/2021

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    DESCRIPTION
    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front-line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    KEY TOPIC AREAS
    HCV: Epidemiology and Screening
    Patient with New Diagnosis of HCV (anti-HCV positive)
    Assessing Severity of Liver Disease in HCV
    Management of the Patient with Chronic HCV
    Management of the Chronic HCV Patient with Co-Morbid and Other Conditions
    Antiviral Treatment of the Patient with HCV Infection
    Management of Patients with HCV who have Achieved a Virological "Cure"
    The Pediatric Patient with HCV

    Release date: February 26, 2021
    Expiration date: February 25, 2024
    Time to complete each module: 30 minutes

    CREDITS OFFERED
    Continuing Medical Education (CME): For a maximum of 4.00 AMA PRA Category 1 Credits™  
    Continuing Education (CE): For a maximum of 4.00 Contact Hour 
    You may only earn one Continuing Education Credit type - either CME or CE

    Maintenance of Certification (MOC): For a maximum of 4.00 MOC Points

    COMPONENTS
    Online presentations comprised of:

    -8 online interactive, narrated modules 15 to 20 minutes in length
    -Pre- and post-test questions for each module
    -Evaluation for CME or CE credit offering 

    DIRECTIONS
    Click "Register" to activate the enduring material. Review all section tabs before you begin. Select module of interest. Complete all components to claim either CME or CE. MOC is available for learners who complete and earn CME.

    COPYRIGHT 
    All faculty in this activity have given their permission for publication ©2021 AASLD. 

    CONTACT INFORMATION 
    For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org 
    For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

    Learning Objectives:
    • Identify patients with liver disease
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for different liver diseases
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Pharmacists
    Physician Assistants
    Transplant Coordinators
    Surgeons
    Fellows/Trainees
    Primary Care Physicians
    Other healthcare providers

    CREDITS OFFERED 
    Continuing Medical Education (CME): For a maximum of 4.00 AMA PRA Category 1 Credits™ 
    Maintenance of Certification (MOC): For a maximum of 4.00 MOC Points
    Continuing Education (CE): For a maximum of 4.00 Contact Hours

    ACCREDITATION AND DESIGNATION STATEMENTS 
    Continuing Medical Education (CME) 
    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 4.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) 
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    image

    Continuing Education (Nursing Contact Hours)  
    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 4.00 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    CLAIMING CME CREDITS 
    Physicians and other health care professionals for a maximum of 4.00 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by February 25, 2024

    CLAIMING CE CREDITS
    Nurses for a maximum of 4.00 contact hours for this enduring continuing education material must be completed by February 25, 2024

    CLAIMING ABIM MOC POINTS  
    Physicians seeking ABIM MOC credit must complete the enduring material by February 25, 2024. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through February 2024 for individuals who successfully complete MOC.

    HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

                 o    Complete the pre-tests

                 o    Watch video presentations

                 o    Complete the post-tests and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing  score.)

                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

    MOC points are available for ABIM board certified physicians only.

    DISCLOSURE OF CONFLICTS OF INTEREST 
    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The enduring material organizers, faculty, reviewers and staff have reported the following disclosures:

    John W. Ward, MD
    Faculty
    General non-binding support: Abbott, Roche, AbbVie, Siemens, AASLD, EASL, Zydus Cadilla, Cepheid, Asian Liver Center, John Martin Foundation, Gilead Sciences, US CDC, PHARCO and individuals

    Nancy Reau, MD, FAASLD
    Faculty
    Grant/Research Support: AbbVie, Gilead Sciences
    Faculty/Advisory Committee or Review Panels: AbbVie, Gilead Sciences

    Jordan J. Feld, MD, MPH, FAASLD
    Faculty
    Grant/Research Support: AbbVie, Eiger, Enanta, Gilead Sciences, Janssen and Wako/Fujifilm
    Faculty/Advisory Committee or Review Panels: AbbVie, Arbutus, Eisai, Gilead Sciences, GSK and Roche

    Sanjeev Arora, MD, FAASLD
    Faculty
    Nothing to disclose

    Raymond T. Chung, MD, FAASLD
    Faculty
    Grant/Research Support: AbbVie, Gilead Sciences, Merck, BMS, Janssen, Boehringer and Roche

    Jennifer Price, MD, PhD
    Faculty
    Grant/Research Support: Gilead Sciences and Merck
    Consulting: Theratechnologies
    Ownership Interest (Spouse): AbbVie, Bristol-Myers Squibb, Johnson and Johnson and Merck

    Michael W. Fried, MD, FAASLD
    Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and multiple NIH Grants
    Consulting: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen and Merck

    Andrew J. Muir, MD, FAASLD
    Grant/Research Support: AbbVie, Gilead Sciences and Merck
    Faculty/Advisory Committee or Review Panels: AbbVie and Gilead Sciences

    Kathleen B. Schwarz, MD, FAASLD
    Grant/Research Support: NIDDK, Roche/Genentech and Gilead Sciences
    Consulting: Sarepta, Up-to-Date and Mirium 

    Lauren A. Beste, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose 

    Amanda J. Chaney, DNP, APRN, FNP-BC
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Royalities: Springer Publishing-Author 

    Rena Fox, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Grant/Research Support: Gilead Sciences

    Leslie Hayes, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose 

    Sonal Kumar, MD
     
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead Sciences, Intercept and AbbVie 
    Speaker's Bureau: Gilead Sciences and AbbVie
    Grant/Research Support: Gilead Sciences, AbbVie and Intercept

    Adam Mikolajczyk, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Amol Rangnekar, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Raj Vuppalanchi, MD, FAASLD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Susan Zapatka, DNP 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Dominique Clayton 
    AASLD Staff
    Nothing to disclose

    Denise Seise
    AASLD Staff
    Nothing to disclose

    Sheryl Morgan 
    Amedco LLC Staff
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support:
    No commercial support was received for this enduring material activity.


  • 2021 Webinar: Use of Serum and Imaging Biomarkers of NAFLD/NASH in Clinical Practice

    Contains 2 Component(s) Recorded On: 02/17/2021

    Webinar hosted by the Nonalcoholic Fatty Liver Disease Special Interest Group on February 17, 2021.

    This on-demand webinar will update the audience on the most recent data in non-invasive testing (NITs) biomarkers in NAFLD/NASH (including use for staging, monitoring disease progression and response to therapy). We will focus on three key areas: serum-based biomarkers, imaging-based biomarkers and how to use combination or sequential NITs. At the conclusion of the webinar, learners will have an update on knowledge of various biomarkers in NAFLD and a path to apply best practices in their setting.

    Emmanuel A. Tsochatzis

    Emmanuel A. Tsochatzis, MD, PhD, MSc, FEBTM, FRCP is a professor of hepatology at the UCL Institute for Liver and Digestive Health in the Royal Free Hospital, London, UK and head of the Centre for Metabolic Liver Diseases. He leads the specialist multidisciplinary service in NAFLD at the Royal Free Hospital and has an active research program in NAFLD. His clinical and research interests include NAFLD, non-invasive fibrosis assessment, cirrhosis and portal hypertension. Professor Tsochatzis finished his specialty training and PhD in Hippokration General Hospital in Greece, before moving to the Royal Free Hospital for his post-doc research under Professor Andy Burroughs. Since 2019, he is a member of the Scientific Committee and Governing Board of EASL.

    Professor Tsochatzis is the section editor for liver disease in BMC Gastroenterology and in the editorial board of Liver International. He was a member of the editorial board of HEPATOLOGY from 2017 to 2019. He is a member of the steering committee of the Baveno collaboration for portal hypertension. He led several international research collaborations resulting in more than 220 publications in peer reviewed journals. His work on the cost-effectiveness of non-invasive fibrosis tests has informed the WHO guidelines on diagnosis and treatment of both HBV and HCV. He designed and implemented a primary care pathway for NAFLD referrals to secondary care. He received funding for his research from NIHR, EASL and EU Horizon 2020.

    Mohammad Shadab Siddiqui

    Mohammad Shadab Siddiqui, MD is an associate professor of medicine at Virginia Commonwealth University in the Division of Gastroenterology and Hepatology. His clinical and research interest are largely in nonalcoholic fatty liver disease (NAFLD). More specifically, he is interested in the liver-heart axis and metabolic complications of NAFLD. This research spans full spectrum on NAFLD that includes early disease, cirrhosis and post-LT NAFLD. He also has an interest in biomarker development and regulatory science. In his publications, he demonstrated the impact that NAFLD has on lipoprotein metabolism and the clinical implications of this impact. His work in the cirrhosis cohort attempted to better define cardiovascular risk assessment prior to liver transplantation. Furthermore, his publications have also provided additional insight on CVD after LT.

    Dr. Siddiqui is a member of the Liver Forum and was the lead author on the NAFLD Case Definition manuscript. He is part of the AASLD Liver Transplantation Education Committee. Additionally, he is an active member of the AASLD NAFLD and Liver Transplantation SIG. He remains active within the NAFLD research space serving as the site-PI for multiple clinical trials and was the national PI for the multi-center NASH trial for the saroglitazar. He is also an active member of the NailNASH consortium, which is a multi-center collaboration between academic centers across the US that aims to better understand post-liver transplant NAFLD. In addition to his clinical and research involvement, he is an active teacher and educator at Virginia Commonwealth University. He mentors many trainees from undergraduates, post-graduate and medical students, residents and fellows.

    Alina M. Allen

    Alina M. Allen, MD is an assistant professor of medicine in the Division of Gastroenterology and Hepatology and the director of the NAFLD Clinic at Mayo Clinic Rochester, Minnesota. She is an NIH-funded investigator in the field of nonalcoholic fatty liver disease (NAFLD) with clinical expertise in liver diseases before and after liver transplantation. Her research interest includes the development of noninvasive biomarkers for the diagnosis of nonalcoholic steatohepatitis (NASH) and pathways to improve the identification and management of patients with NAFLD. Her research program includes biorepositories/biomarker databases, longitudinal population-based studies of natural history and clinical trials.

    Dr. Allen is actively involved in national societies as a member of the NAFLD Special Interest Group within the American Association for the Study for Liver Diseases (AASLD) and as a GRADE methodologist of the Clinical Practice Guideline Committee of the American Gastroenterology Association. She serves on the Editorial Board of HEPATOLOGY, the AASLD Publications Committee and the Annual Meeting Education Committee. She has served as chair of the AGA Abstract Committee for Non-Alcoholic Fatty Liver Diseases (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) for the past three years.

    Kathleen E. Corey (Moderator)

    Kathleen Corey, MD, MPH, MMSc is the director of the Massachusetts General Hospital Non-Alcoholic Fatty Liver Disease (NAFLD) Clinic, associate program director for the medicine residency for clinical and translational research, hepatologist with a specialty in NAFLD, physician investigator in the CTEU and an assistant professor of medicine at Harvard Medical School. Dr. Corey earned her medical degree at Duke University School of Medicine, her master’s in public health from the University of North Carolina and master’s in medical science from Harvard Medical School. Prior to joining the faculty of Massachusetts General Hospital (MGH), she completed her training in internal medicine, chief residency, gastroenterology and advanced hepatology and liver transplant at MGH.

    Dr. Corey’s interests include clinical and translational research in NAFLD. She aims to better understand predictors of development and progression of NAFLD, the interplay between cardiovascular disease and NAFLD and the natural history of NAFLD in persons living with HIV (PLWH). She is the co-private investigator for an R01 evaluating the role of tesamorelin, a growth hormone-releasing hormone for the treatment of NAFLD and is involved in an NIH-funded study on the prevalence, risk factors and treatment of NAFLD in PLWH.

  • 2021 Webinar: Developing a Career in Clinical Research

    Contains 2 Component(s) Recorded On: 02/10/2021

    Webinar hosted by the Hepatitis B Special Interest Group on February 10, 2021.

    This live webinar will focus on identifying areas of unmet needs and developing a research career. We will have four presenters share their career experiences. An experienced professional will share her experience on doing clinical research in hepatitis B and thoughts on selecting between research, quality improvement or medical educator. Three young investigators will present their perspectives on how his or her career started and share in future career plans.

    Gerd Kullak-Ublick

    Gerd Kullak-Ublick, MD is a Professor of Clinical Pharmacology and Toxicology at the University of Zurich and Department Head at the University Hospital Zurich, Switzerland. He additionally serves as the Global Head of Mechanistic Safety and Chair of the Hepatic Safety Team at Novartis Pharma, Basel. Dr. Kullak-Ublick went to medical school at the Universities of Bonn, Stanford, London and Munich and received his MD from Munich University in 1990.  Dr. Kullak-Ublick served his residency in Internal Medicine, Gastroenterology and Clinical Pharamacology/Toxicology at the University Hospitals of Munich and Zurich and conducted his postdoctoral research in Zurich, in collaboration with Allan Wolkoff at the Liver Centre, Albert Einstein College of Medicine, Bronx/New York. He obtained Board Certification in Internal Medicine (1998), Gastroenterology (2002) and Clinical Pharmacology and Toxicology (2005). He is coauthor of the 2019 EASL Clinical Practice Guideline on Drug-Induced Liver Injury, as well as on the 2020 CIOMS consensus report on Drug-Induced Liver Injury.

    Kali Zhou

    Kali Zhou, MD, MAS is a transplant hepatologist and assistant professor in the Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California. She received her medical degree from Feinberg School of Medicine at Northwestern University, completed an internal medicine residency at the University of California, Los Angeles, and a T32 gastroenterology and transplant hepatology fellowship at the University of California, San Francisco, where she also completed a master’s in clinical research. She holds committee positions in the AASLD HBV and Public Health SIGs.

    Dr. Zhou investigated the epidemiology of HCV in Southern China as a Fulbright scholar and has published numerous peer-reviewed manuscripts and reviews related to epidemiology and health services delivery for chronic HBV infection. Her current research program focuses on disparities in liver cancer and utilizing novel geospatial approaches to improve cancer equity and outcomes for multi-ethnic populations. She is also grant funded to study the impact of immigration and acculturation on completing guideline-based HBV metrics. She was awarded the Early Career Investigator Award in Clinical/Translational Science by AASLD for her work.

    Hannah Lee

    Hannah Lee, MD is an assistant professor of medicine at Virginia Commonwealth University Medical Center in Richmond, Virginia in the division of GI, Hepatology and Nutrition. She has a strong interest in liver cancer and viral hepatitis, particularly hepatitis B. She was previously the director of the Asian Pacific Liver Health Program in Boston Chinatown at Tufts Medical Center. She is currently co-director of the multidisciplinary liver cancer program at VCU and practices both transplant and general hepatology. She is involved in multicenter studies evaluating the natural history of HBV and HCC.

    Dr. Lee’s career has been focused on addressing health disparities in liver disease, particularly among disproportionately affected minority groups with chronic hepatitis B. Some of her work has focused on screening and linkage to care. She has been involved in education and outreach both locally and nationally in addressing liver health disparities in hepatitis B and hepatocellular carcinoma among various communities in the United States. Dr. Lee currently serves on the AASLD Hepatitis B Special Interest Group's Leadership Steering Committee and is co-chair of the Education Subcommittee. She also serves as a committee member on the AASLD Public Policy Committee.

    ​Robert J. Fontana

    Robert J. Fontana, MD, FAASLD, FAGA is a Professor of Medicine and Medical Director of Liver Transplantation at the University of Michigan.  He is a clinical-translational investigator with research interests in viral hepatitis, drug induced liver injury and acute liver failure.  He is co-chair of the Drug Induced Liver Injury Network (DILIN) Steering Committee and an active participant in the Hepatitis B Research Network.   He has also been an active member of the US Acute Liver Failure Study Group since 1998 and is a current Co-PI of this multicenter network.   

    William Proctor (Moderator)

    Will Proctor, PhD, DABT is a Senior Scientist and Senior Director of Predictive Toxicology in the Department of Safety Assessment at Genentech, Inc. Prior to joining Genentech in 2013, Dr. Proctor earned his BS in Chemistry from Trinity College  and PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill in the laboratory of Dr. Dhiren Thakker with a focus on drug transport and pharmacokinetics.  He then performed postdoctoral training at the National Institutes of Health in the laboratory of Dr. Lance Pohl, with research centered on immune mechanisms of drug-induced liver injury (DILI). Will is a board-certified toxicologist and organizational leader with 10 years of experience in investigative and discovery toxicology. At Genentech, Dr. Proctor serves as the Senior Director of Predictive Toxicology, where he oversees the Investigative Toxicology Laboratory, Complex In Vitro Systems Laboratory, and non-clinical safety support for the Small-Molecule Drug Discovery (SMDD) organization. He is also actively involved in several cross-pharma consortia, with leadership roles in the Innovation and Quality (IQ) Microphysiological Systems Affiliate and the Non-clinical Working Group of the IQ DILI Affiliate.  In addition to these activities, Will has continued his research in mechanisms of DILI, including identifying and qualifying preclinical tools to better assess hepatotoxicity risk during drug discovery. 

    Yee Hui Yeo (Moderator)

    Yee Hui Yeo, MD, MSc is a resident doctor at Cedars-Sinai Medical Center. He is an active investigator on viral hepatitis related epidemiological and health outcomes research. He is currently a trainee member of the Hepatitis B SIG Steering Committee, AASLD. He has published more than 40 peer-reviewed publications, including first or co-first authorship of original articles published in Gastroenterology, Journal of Hepatology, HEPATOLOGY and Gut.

    Dr. Yeo has served as associate editor for BMC Gastroenterology. He is interested in harnessing health data analytic tools, modeling, and meta-analysis to determine the epidemiology, cascade of care, natural history, and outcomes of chronic viral hepatitis infection. He uses large databases, multicenter cohorts and EHR data from Cedars-Sinai Medical Center. He has been participating in international consortia of natural history of hepatitis B infection. His works were selected as "Best of the Liver Meeting" in AASLD annual meeting 2018. Yeo is the recipient of "Emerging Liver Scholar Award" in 2019.

  • 2021 Webinar: To Stop or Not to Stop: The Practice of Finite Nucleos(t)ide Analog Therapy

    Contains 2 Component(s) Recorded On: 01/20/2021

    Webinar hosted by the Hepatitis B Special Interest Group on January 20, 2021.

    This one-hour webinar will summarize the data that supports the finite strategy of nucleos(t)ide analog (NA) therapy in patients with chronic hepatitis B. Further discussion on how the presenter practices the strategy. In the second half of the webinar, the presenter will present data that argues against the rationale of a finite NA therapy. The presenter will elaborate on why stopping NA before loss of HBsAg cannot be recommended. We will conclude with a twenty-minute discussion on the gaps in current knowledge, whether and how the practice can be individualized.

    Wen-Juei Jeng

    Rachel Wen-Juei Jeng, MD received her Doctor of Medicine Education from College of Medicine, National Yang-Ming University, Taiwan (1998-2005). She has accomplished internal medicine residency, Gastroenterology fellowship training and becomes a faculty and physician scientist in Department of Gastroenterology and Hepatology in Chang Gung Memorial Hospital, Linkou branch, Taiwan. She currently serves as an Associate Professor in College of Medicine, Chang Gung University since 2019.

    Dr. Jeng’s research interests mainly focus on viral hepatitis (esp. HBV) and clinical hepatology. She has been working with her mentor Prof. Yun-Fan Liaw and published a series of off-Nuc therapy cohort study in Hepatology and Clinical Gastroenterology and HEPATOLOGY. She now serves as a member of TASL, EASL and AASLD.

    Paul H. Hayashi

    Paul “Skip” H. Hayashi, MD, MPH, FAASLD is an adult hepatologist at the FDA.  He is DILI Team Lead in the Division of Hepatology and Nutrition, Office of New Drugs, Center for Drug Evaluation and Research.  Prior to joining the FDA in February of 2020, he held positions in academia, civil service and uniformed service.  He received his BA in microbiology at University of California (UC) Los Angeles and medical degree at UC San Diego.  After completing residency and gastroenterology fellowship at UC Davis, he completed a clinical research fellowship in the Liver Diseases Section, National Institutes of Health, Bethesda, MD as a public health officer.  He then returned to California as Assistant Professor at the Veterans Administration Hospital in Loma Linda, California followed by serving in the US Air Force Medical Corp in Japan and Texas. While in the Air Force he continued clinical research, and then returned to academia by completing a transplant fellowship at the University of Colorado, Denver.  He then served as Assistant Professor and transplant hepatologist at Saint Louis University (SLU), St. Louis, Missouri.  In 2006, he completed a Master of Public Health at SLU.   From 2006, he was Medical Director of Liver Transplantation at the University of North Carolina (UNC), Chapel Hill, and became a Professor of Medicine at UNC before joining the FDA in 2020.  Since 2007, he has been a Co-Principle Investigator in the US Drug-Induced Liver Injury Network (DILIN) and remains Co-Chair of the DILIN’s Causality Committee.  

    Marc Ghany (Moderator)

    Marc G. Ghany, MD, MHSc, FAASLD is an investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis.

    ​Robert J. Fontana (Moderator)

    Robert J. Fontana, MD, FAASLD, FAGA is a Professor of Medicine and Medical Director of Liver Transplantation at the University of Michigan.  He is a clinical-translational investigator with research interests in viral hepatitis, drug induced liver injury and acute liver failure.  He is co-chair of the Drug Induced Liver Injury Network (DILIN) Steering Committee and an active participant in the Hepatitis B Research Network.   He has also been an active member of the US Acute Liver Failure Study Group since 1998 and is a current Co-PI of this multicenter network.   

  • 2021 Webinar: Practical Approach to Coagulation Management in Cirrhosis

    Contains 2 Component(s) Recorded On: 01/11/2021

    Webinar hosted by the Clinical Practice Special Interest Group on January 11, 2021.

    Coagulation disorders in patients with cirrhosis present challenging situations for clinical providers. This one hour webinar will summarize the knowledge behind coagulation disorders in patients with cirrhosis, including the mixed and thrombosis prone model, limitations in current tests of hemostasis, and the dangers of excessive transfusion. Using practical clinical vignettes, learners will gain understanding of best practice to manage these difficult coagulation situations, including in practice settings where colleagues in hospital medicine and interventional radiology may have different approaches. Vignettes will include an outpatient cirrhotic patient with portal vein thrombosis, an inpatient cirrhotic requiring paracentesis, and an inpatient cirrhotic in the intensive care unit with renal failure and spontaneous mucosal bleeding.

    Nicolas Intagliata

    Nicolas Intagliata, MD is an associate professor of medicine at the University of Virginia. His research is based in hemostasis and liver disease. More specifically, the role of anticoagulation in prevention and treatment of thrombosis in cirrhosis and underlying mechanisms of hemostasis and thrombosis in liver disease. His clinical practice involves caring for patients both in the general hepatology and liver transplantation setting.

    Arul Thomas (Moderator)

    Arul M. Thomas, MD is an assistant professor of medicine at the MedStar Georgetown Transplant Institute at Georgetown University Hospital, in Washington, DC. He has interests in all aspects of clinical transplant hepatology, including autoimmune liver diseases, drug induced liver injury and pediatric to adult transition of care. He serves on the Clinical Practice SIG. He practices also at MedStar Washington Hospital Center, where he fulfills a goal to increase access to advanced liver care in underserved communities in the DC area. At all his clinical sites, he is well-known as an avid educator of trainees.

  • 2020 Webinar: New E/M Requirements are Coming January 1: Will You Be Ready?

    Contains 2 Component(s) Recorded On: 12/15/2020

    Webinar hosted by the Public Policy Committee on December 15, 2020.

    On January 1, 2021, the Centers for Medicare & Medicaid Services will be implementing significant changes to the outpatient evaluation and management (E/M) codes (CPT® codes 99202-99215) for new and established patients. The agency revised both the documentation requirements and values. Practices, physicians, and staff must understand these modifications to ensure a successful transition next year. To help prepare, AASLD is holding a webinar to explain these changes, including how to correctly bill and document the revised code set, on December 15 at 3pm ET. Join to learn more about what these changes mean for you and your practice to be prepared on January 1!

    Erika Miller

    Erika Miller, JD, Senior Vice President and Counsel, has 17 years of experience in government relations and has broad experience in Medicare reimbursement policies and appropriations working largely with non- profit organizations ranging from medical specialty societies, coalitions, and patient advocacy organizations. Erika has expertise in the intricacies of Medicare coding and reimbursement and provides guidance to clients as they navigate the evolving area of health care payment and quality. Erika is a co-author of a chapter entitled, “Lobbying the Appropriations Process” in the American Bar Association Lobbying Manual.

    A New Jersey native, Erika worked in the office of Congressman Steve Rothman of New Jersey where she handled immigration issues. Erika also worked in the U.S. Department of Health and Human Services Office on Women's Health, where she monitored grant awards. Prior to joining CRD Associates in 2005, Erika worked at the lobbying firm of Broydrick & Associates representing health care interests. She served as co-chair of the Women in Government Relations Health & Social Polices Task Force and is member of the group Women Business Leaders in Health Care. Erika received her law degree from The American University, where she was an editor of the Administrative Law Review. She earned an undergraduate degree in Political Science from Colgate University. 

  • 2020 Webinar: Chronic Hepatitis C 500: The Advanced Course

    Contains 2 Component(s) Recorded On: 12/02/2020

    Webinar hosted by the Hepatitis C Special Interest Group on December 2, 2020.

    Many HCV-infected patients suffer from decompensated cirrhosis. Aside from appropriate care of their cirrhosis, these patients may benefit from therapy, irrespective of liver transplant candidacy. Providers outside of transplant centers, should be knowledgeable about pertinent aspects of liver transplants for their patients. Finally, several groups have reported unusual genotype subtypes which are less responsive to existing DAA regimens. This webinar is designed for the experienced HCV-treatment provider.

    Brian Pearlman

    Brian L. Pearlman, MD is Medical Director for Wellstar Atlanta Medical Center’s Center for Hepatitis C in Atlanta Georgia. He is also Professor of Medicine at the Medical College of Georgia and Professor of Medicine at Emory School of Medicine. Dr. Pearlman completed his medical degree at the University of Miami, Florida and his post-graduate training included both Diagnostic Radiology at University of Texas-Southwestern and Internal Medicine at Baylor University-Dallas, Texas.

    Dr. Pearlman is Faculty for the American College of Physicians (FACP), Fellow of the American Association for the Study of Liver Diseases (FAASLD), and members of the American Academy of HIV Medicine, and the American Gastroenterological Association. He sat on the Board of Directors for The American Liver Foundation’s Southeast Chapter. Dr. Pearlman is widely published in leading journals such as The Lancet, Gastroenterology, HEPATOLOGY, The American Journal of Gastroenterology, The Lancet Infectious Disease, Clinical Infectious Diseases and The American Journal of Medicine.

    Dr. Pearlman is active in both patient care and in teaching physicians. He has been the recipient of numerous teaching awards, and also an active investigator in multiple hepatitis C-related trials, some of which are in collaboration with the CDC’s Division of Viral Hepatitis.

    Preeti A. Reshamwala

    Preeti A. Reshamwala, MD is a Distinguished Physician in Transplant Hepatology at Emory University School of Medicine. She is the director of The Fatty Liver Clinic, and the program director for the Transplant Hepatology Fellowship Program.

    Dr. Reshamwala has participated in over 21 clinical trials on the treatment of Hepatitis C. She co-directs the management and treatment of patients with hepatitis C who are on the waitlist for liver transplantation at Emory University, and hepatitis C treatment for patients after transplantation. She has been an advocate for using hepatitis C positive donors for liver transplant recipients who have not been exposed to Hepatitis C.

    Jean-Michel Pawlotsky

    Jean-Michel Pawlotsky, MD, PhD is professor of medicine at the University of Paris-Est. He is the director of the National Reference Center for Viral Hepatitis B, C and D and of the Department of Virology at the Henri Mondor University Hospital in Créteil, France, and director of research team “Viruses-Hepatology-Cancers“ at the Mondor Institute of Biomedical Research (INSERM U955). He focuses on teaching and research in virology (primarily hepatitis viruses) and liver oncology. Dr. Pawlotsky earned his medical degree in Hepatology and Gastroenterology in 1992. In addition, he earned a Thesis in molecular virology from the University of Paris, France, and he is a graduate in virology from the Pasteur Institute in Paris and microbiology from the University of Paris. Dr. Pawlotsky has been acting as the Secretary General of the European Association for the Study of the Liver (EASL) between 2005 and 2009.

    Dr. Pawlotsky is a member of the Strategic Committee of the National Agency for Research on AIDS and Viral Hepatitis (ANRS). He has been an associate editor of HEPATOLOGY, the official journal of the American Association for the Study of Liver Diseases (AASLD), between 2001 and 2006, and an associate editor of Gastroenterology, the official journal of the American Gastroenterological Association (AGA), between 2011 and 2016. Dr. Pawlotsky’s noted career contributions include the publication of over 500 articles and book chapters in his areas of expertise and over 650 invited lectures at international meetings.

    Omar Massoud (Moderator)

    Omar Massoud, MD, PhD, FAASLD is an associate professor of medicine at the University of Alabama at Birmingham. He is the director of clinical liver research at the University of Alabama Liver Center. He is a member of the AASLD Publication Committee and Hepatitis C Special Interest Group Steering Committee. He earned his Doctor of Medicine degree from Al-Azhar University, Cairo, Egypt. He completed residency in Internal Medicine at Case Western Reserve University, Cleveland, Ohio, followed by Fellowship in Gastroenterology and Hepatology at the Medical College of Wisconsin, Milwaukee, Wisconsin. He completed a fellowship in Transplant Hepatology at Mayo Clinic, Rochester, Minnesota.

    Dr. Massoud was the PI of the large CDC study on Birth Cohort HCV screening (2011-2016). The results of this study lead to change in HCV screening national guidelines. He is also the PI of several government and industry sponsored studies on HCV and NASH. He has numerous publications and presentations on HCV and NASH. He mentored many trainees and young faculty throughout their career.

    Photo of Omar Massoud, MD, PhD, FAASLD

  • 2020 Patient Debrief Topline Clinical Research – What this Means for Patients

    Product not yet rated Contains 2 Component(s) Recorded On: 11/17/2020

    Patient Debrief Topline Clinical Research – What this Means for Patients presented at The Liver Meeting Digital Experience

    Don’t overlook any of the research presented at TLMdX that directly impacts patients. New this year, an patient advocate will briefly review of all the abstracts presented at the meeting that significantly impacted the role of the patient in one condensed session.